Mylotarg, fludarabine, cytarabine (Ara-C) and cyclosporine (MFAC) combination regimen in patients with CD33-positive primary resistant or relapsed acute myeloid leukemia (AML).

被引：0
|
作者：
Tsimberidou, AM [1 ]
Estey, E [1 ]
Cortes, J [1 ]
Thomas, D [1 ]
Garcia-Manero, G [1 ]
Faderl, S [1 ]
Verstovesk, S [1 ]
O'Brien, S [1 ]
Kantarjian, H [1 ]
Giles, F [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1317
引用
收藏
页码：339A / 340A
页数：2
相关论文
共 50 条
  • [41] Comparison of the cyclophosphailiide (C), ara-c (A), topotecan (T), (CAT) regimen to ara-c plus topotecan or idarubicin (I) as initial therapy for patients with adverse abnormal karyotype acute myeloid leukemia (AML).
    Beran, H
    Giles, FJ
    Cortes, JE
    Thomas, DA
    Koller, C
    O'Brien, SM
    Keating, MJ
    Freireich, E
    Kantarjian, HM
    Estey, E
    BLOOD, 1999, 94 (10) : 226B - 226B
  • [42] A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia
    Stein, Eytan M.
    Walter, Roland B.
    Erba, Harry P.
    Fathi, Amir T.
    Advani, Anjali S.
    Lancet, Jeffrey E.
    Ravandi, Farhad
    Kovacsovics, Tibor
    DeAngelo, Daniel J.
    Bixby, Dale
    Faderl, Stefan
    Jillella, Anand P.
    Ho, Phoenix A.
    O'Meara, Megan M.
    Zhao, Baiteng
    Biddle-Snead, Charles
    Stein, Anthony S.
    BLOOD, 2018, 131 (04) : 387 - 396
  • [43] Clofarabine is active in combination with cytarabine (ara-C) in adult patients (pts) in first relapsed and primary refractory acute leukemia and high-risk myelodysplastic syndrome (MDS).
    Faderl, S
    Gandhi, V
    Garcia-Manero, G
    Thomas, DA
    Cortes, JE
    O'Brien, S
    Estey, E
    Craig, A
    Weiss, J
    Keating, M
    Verstovsek, S
    Giles, FJ
    Kwari, M
    Plunkett, W
    Kantarjian, HM
    BLOOD, 2003, 102 (11) : 615A - 615A
  • [44] Autophagy induction of Acute Myeloid Leukemia (AML) cells after treatment with low dose-cytarabine (Ara-C) and enhanced cytocidal effect on AML cells by combined treatment with ara-c plus lenograstim
    Tang, Yongmin
    Li, Lixia
    Wang, Di
    Shen, Hongqiang
    Qian, Baiqin
    Luo, Chunfang
    Zhang, Haizhong
    BLOOD, 2007, 110 (11) : 114B - 114B
  • [45] Phase I study of clofarabine plus Idarubicin and Clofarabine plus Idarubicin plus Cytarabine (ARA-C) in patients (PTS) with relapsed and primary refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloid blast phase of chronic myeloid leukemia (CML).
    Faderl, S
    Ferrajolil, A
    Wierda, W
    Verstovsek, S
    Ravandi-Kashani, F
    Garcia-Manero, G
    Estey, E
    Thomas, DA
    Kornblau, S
    Kwari, M
    Gandhi, V
    Kantarjian, HM
    BLOOD, 2004, 104 (11) : 501A - 501A
  • [46] Phase I study of UCN-01 and ara-C for patients with refractory or relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Cortes, J
    Plunkett, WK
    Estey, EH
    Keating, MJ
    Madden, T
    Sampath, D
    Faderl, S
    Beran, M
    Dancey, J
    Kantarjian, HM
    BLOOD, 2001, 98 (11) : 211B - 211B
  • [47] The CADET regimen (carboplatin/ara-c/daunorubicin/etoposide/thioguanine) in acute myeloid leukemia (AML): Results in standard-risk patients.
    Spiers, A
    Saba, H
    Balducci, L
    Moscinski, L
    Richard, J
    Huegel, V
    Daniel, P
    Cosgrove, D
    BLOOD, 1995, 86 (10) : 3111 - 3111
  • [48] A pilot study of continuous infusion ara-C in combination with rhG-CSF in relapsed childhood acute myeloid leukemia
    Laver, J
    Shearer, P
    Krance, R
    Hurwitz, CA
    Srivastava, DK
    Weinstein, HJ
    Mirro, J
    LEUKEMIA & LYMPHOMA, 1997, 26 (5-6) : 589 - 593
  • [49] Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients
    Russo, D
    Malagola, M
    Vivo, A
    Fiacchini, M
    Martinelli, G
    Piccaluga, PP
    Damiani, D
    Candoni, A
    Michielutti, A
    Castelli, M
    Testoni, N
    Ottaviani, E
    Rondoni, M
    Pricolo, G
    Mazza, P
    Zuffa, E
    Zaccaria, A
    Raspadori, D
    Bocchia, M
    Lauria, F
    Bonini, A
    Avanzini, P
    Gugliotta, L
    Visani, G
    Fanin, R
    Baccarani, M
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (02) : 172 - 179
  • [50] Clofarabine plus cytarabine (ara-C) is an active induction regimen for newly diagnosed patients (pts) ≤ age 50 with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MOS).
    Faderl, S
    Gandhi, V
    Giles, F
    Estey, E
    Garcia-Manero, G
    O'Brien, S
    Wierda, W
    Kwari, M
    Craig, A
    Kantarjian, HM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 584S - 584S
12345